ES2630002T5 - Fármaco anticanceroso que contiene alfa,alfa,alfa-trifluorotimidina e inhibidor de timidina fosforilasa - Google Patents

Fármaco anticanceroso que contiene alfa,alfa,alfa-trifluorotimidina e inhibidor de timidina fosforilasa Download PDF

Info

Publication number
ES2630002T5
ES2630002T5 ES06712292T ES06712292T ES2630002T5 ES 2630002 T5 ES2630002 T5 ES 2630002T5 ES 06712292 T ES06712292 T ES 06712292T ES 06712292 T ES06712292 T ES 06712292T ES 2630002 T5 ES2630002 T5 ES 2630002T5
Authority
ES
Spain
Prior art keywords
cancer
dose
ftd
therapeutic drug
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES06712292T
Other languages
English (en)
Spanish (es)
Other versions
ES2630002T3 (es
Inventor
Tomohiro Emura
Akira Mita
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taiho Pharmaceutical Co Ltd
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36740357&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2630002(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US11/042,059 external-priority patent/US7799783B2/en
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2630002T3 publication Critical patent/ES2630002T3/es
Publication of ES2630002T5 publication Critical patent/ES2630002T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES06712292T 2005-01-26 2006-01-25 Fármaco anticanceroso que contiene alfa,alfa,alfa-trifluorotimidina e inhibidor de timidina fosforilasa Expired - Lifetime ES2630002T5 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US42059 2005-01-26
US11/042,059 US7799783B2 (en) 2005-01-26 2005-01-26 Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor
JP2005165156 2005-06-06
JP2005165156 2005-06-06
PCT/JP2006/301097 WO2006080327A1 (ja) 2005-01-26 2006-01-25 α，α，α－トリフルオロチミジンとチミジンホスホリラーゼ阻害剤とを配合した抗癌剤

Publications (2)

Publication Number Publication Date
ES2630002T3 ES2630002T3 (es) 2017-08-17
ES2630002T5 true ES2630002T5 (es) 2024-09-19

Family

ID=36740357

Family Applications (1)

Application Number Title Priority Date Filing Date
ES06712292T Expired - Lifetime ES2630002T5 (es) 2005-01-26 2006-01-25 Fármaco anticanceroso que contiene alfa,alfa,alfa-trifluorotimidina e inhibidor de timidina fosforilasa

Country Status (20)

Country Link
EP (1) EP1849470B2 (ref)
JP (1) JP5576591B2 (ref)
KR (1) KR101468216B1 (ref)
AU (1) AU2006209547C1 (ref)
BE (1) BE2017C028I2 (ref)
CA (1) CA2594713A1 (ref)
CY (2) CY1119393T1 (ref)
DK (1) DK1849470T4 (ref)
ES (1) ES2630002T5 (ref)
FI (1) FI1849470T4 (ref)
FR (1) FR17C1028I2 (ref)
HU (2) HUE033306T2 (ref)
LT (2) LT1849470T (ref)
LU (1) LUC00036I2 (ref)
NL (1) NL300889I2 (ref)
PL (1) PL1849470T5 (ref)
PT (1) PT1849470T (ref)
SI (1) SI1849470T2 (ref)
TW (1) TWI362265B (ref)
WO (1) WO2006080327A1 (ref)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
EP1849470B2 (en) 2005-01-26 2024-03-20 Taiho Pharmaceutical Co., Ltd. Anticancer drug containing alpha, alpha, alpha-trifluorothymidine and thymidine phosphorylase inhibitor
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
WO2008132443A1 (en) 2007-04-25 2008-11-06 Cyclacel Limited Use of sapacitabine to treat proliferative disease
CA2713128C (en) 2008-01-25 2016-04-05 Gruenenthal Gmbh Pharmaceutical dosage form
BRPI0912014A2 (pt) 2008-05-09 2019-03-06 Grünenthal GmbH processo para a preparação de uma formulação em pó intermediária e uma forma de dosagem sólida final sob uso de uma etapa de congelamento por atomização
AU2009248037A1 (en) * 2008-05-15 2009-11-19 Katholieke Universiteit Leuven, K.U. Leuven R&D Anti-cancer combination therapy
RU2015138422A (ru) 2009-07-22 2018-12-25 Грюненталь Гмбх Стабильная при окислении, прочная на излом лекарственная форма
CN102573805A (zh) 2009-07-22 2012-07-11 格吕伦塔尔有限公司 热熔挤出的控制释放剂型
BR112013005234A2 (pt) 2010-09-02 2016-05-03 Gruenenthal Gmbh forma de dosagem resistente à violação compreendendo um polímero aniônico.
NZ607392A (en) 2010-09-02 2015-03-27 Gruenenthal Chemie Tamper resistant dosage form comprising inorganic salt
RS56527B1 (sr) 2011-07-29 2018-02-28 Gruenenthal Gmbh Tableta za trenutno oslobađanje leka rezistentna na zloupotrebu
PE20141638A1 (es) 2011-07-29 2014-11-22 Gruenenthal Chemie Tableta a prueba de manipulacion que proporciona liberacion de farmaco inmediato
EP2746404B1 (en) 2011-08-16 2017-12-06 Taiho Pharmaceutical Co., Ltd. Antitumor agent and therapeutic effect prediction method for patients with kras-mutated colorectal cancer
TWI526210B (zh) * 2012-02-15 2016-03-21 Taiho Pharmaceutical Co Ltd Oral pharmaceutical composition
TWI503122B (zh) * 2012-02-15 2015-10-11 Taiho Pharmaceutical Co Ltd Oral administration of pharmaceutical compositions
MX356421B (es) 2012-02-28 2018-05-29 Gruenenthal Gmbh Forma de dosificacion resistente a la manipulacion indebida que comprende un compuesto farmacologicamente activo y un polimero anionico.
DK2838512T3 (en) 2012-04-18 2018-11-19 Gruenenthal Gmbh MANIPULATED AND DOSAGE DUMPED PHARMACEUTICAL DOSAGE FORM
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
SG11201406550QA (en) * 2012-05-16 2014-11-27 Novartis Ag Dosage regimen for a pi-3 kinase inhibitor
TWI615145B (zh) 2013-03-27 2018-02-21 Taiho Pharmaceutical Co Ltd 含伊立替康鹽酸鹽水合物之抗腫瘤劑
AU2014245147B2 (en) 2013-03-27 2017-08-31 Les Laboratoires Servier Antitumor agent including low-dose irinotecan hydrochloride hydrate
US20160082032A1 (en) 2013-05-17 2016-03-24 Taiho Pharmaceutical Co., Ltd. Therapeutic effect prediction method for colorectal cancer patient in whom expression of tk1 protein has increased
AR096439A1 (es) 2013-05-29 2015-12-30 Gruenenthal Gmbh Forma de dosificación resistente al uso indebido que contiene una o más partículas
JP6445537B2 (ja) 2013-05-29 2018-12-26 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング １個または複数の粒子を含有する改変防止（ｔａｍｐｅｒ−ｒｅｓｉｓｔａｎｔ）剤形
US10624862B2 (en) 2013-07-12 2020-04-21 Grünenthal GmbH Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
UA121538C2 (uk) 2013-09-06 2020-06-25 Тайхо Фармасьютікал Ко., Лтд. Спосіб лікування злоякісного новоутворення
AU2014356581C1 (en) 2013-11-26 2020-05-28 Grunenthal Gmbh Preparation of a powdery pharmaceutical composition by means of cryo-milling
MX2016014738A (es) 2014-05-12 2017-03-06 Gruenenthal Gmbh Formulacion en capsula de liberacion inmediata resistente a alteraciones que comprende tapentadol.
MX2016015417A (es) 2014-05-26 2017-02-22 Gruenenthal Gmbh Multiparticulas protegidas contra vertido de dosis etanolico.
JP2018517676A (ja) 2015-04-24 2018-07-05 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 即時放出および溶媒抽出に対する耐性を有する改変防止製剤
AU2016319203A1 (en) 2015-09-10 2018-02-22 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
UA125119C2 (uk) * 2016-01-08 2022-01-12 Тайхо Фармасьютікал Ко., Лтд. Протипухлинний засіб, що містить імуномодулятор і підсилювач протипухлинного ефекту
UA123403C2 (uk) 2016-02-05 2021-03-31 Тайхо Фармасьютікал Ко., Лтд. Спосіб лікування хворих на рак з тяжкою нирковою недостатністю
WO2019124544A1 (ja) 2017-12-22 2019-06-27 大鵬薬品工業株式会社 トリフルリジン及び／又はチピラシル由来の類縁物質の検出方法
US10866219B2 (en) 2017-12-22 2020-12-15 Taiho Pharmaceutical Co., Ltd. Method for detecting trifluridine- and/or tipiracil-related substance
WO2019135405A1 (ja) 2018-01-05 2019-07-11 大鵬薬品工業株式会社 トリフルリジン由来の類縁物質の検出方法
US10816517B2 (en) 2018-01-05 2020-10-27 Taiho Pharmaceutical Co., Ltd. Method for detecting trifluridine-related substance by high-performance liquid chromatography
WO2026019875A1 (en) * 2024-07-17 2026-01-22 Jnd Therapeutics, Inc. Methods and formulations for treatment of liver cancer using trifluridine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69629156T2 (de) 1995-03-29 2004-05-06 Taiho Pharmaceutical Co. Ltd. Uracilderivate und diese enthaltende antitumoreffekt-verstärker sowie antitumormittel
US6255314B1 (en) * 1996-09-24 2001-07-03 Taiho Charmaceutical Co., Ltd. Cancerous metastasis inhibitors containing uracil derivatives
EP1849470B2 (en) 2005-01-26 2024-03-20 Taiho Pharmaceutical Co., Ltd. Anticancer drug containing alpha, alpha, alpha-trifluorothymidine and thymidine phosphorylase inhibitor

Also Published As

Publication number Publication date
AU2006209547B2 (en) 2011-05-26
CA2594713A1 (en) 2006-08-03
PL1849470T5 (pl) 2024-06-10
PT1849470T (pt) 2017-09-22
LTPA2017024I1 (lt) 2017-08-10
SI1849470T1 (sl) 2017-10-30
BE2017C028I2 (ref) 2025-09-10
RU2007132181A (ru) 2009-03-10
LUC00036I1 (ref) 2017-10-02
CY2017029I1 (el) 2018-02-14
KR20070104559A (ko) 2007-10-26
SI1849470T2 (sl) 2024-05-31
HUS1700032I1 (hu) 2017-09-28
PL1849470T3 (pl) 2017-11-30
JP5576591B2 (ja) 2014-08-20
FR17C1028I1 (ref) 2017-09-29
EP1849470A1 (en) 2007-10-31
LUC00036I2 (ref) 2017-12-01
LT1849470T (lt) 2017-07-25
CY1119393T1 (el) 2018-02-14
TW200637562A (en) 2006-11-01
FI1849470T4 (fi) 2024-03-22
JPWO2006080327A1 (ja) 2008-06-19
EP1849470B2 (en) 2024-03-20
DK1849470T4 (en) 2024-04-02
WO2006080327A1 (ja) 2006-08-03
FR17C1028I2 (fr) 2018-11-02
HUE033306T2 (hu) 2017-11-28
NL300889I1 (nl) 2017-08-14
EP1849470B1 (en) 2017-06-21
CY2017029I2 (el) 2018-02-14
EP1849470A4 (en) 2010-12-08
LTC1849470I2 (lt) 2019-10-25
AU2006209547A1 (en) 2006-08-03
NL300889I2 (nl) 2018-01-16
RU2394581C2 (ru) 2010-07-20
TWI362265B (en) 2012-04-21
ES2630002T3 (es) 2017-08-17
DK1849470T3 (en) 2017-08-14
AU2006209547C1 (en) 2022-04-07
KR101468216B1 (ko) 2014-12-03

Similar Documents

Publication Publication Date Title
ES2630002T3 (es) Fármaco anticanceroso que contiene alfa,alfa,alfa-trifluorotimidina e inhibidor de timidina fosforilasa
USRE46284E1 (en) Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor
KR20100091978A (ko) 시티딘 탈아미노효소 억제제로서 2'-플루오로-2'-데옥시테트라하이드로우리딘
ES2385850T3 (es) Potenciador de radioterapia
JP2025013684A (ja) 重度腎機能障害を有する癌患者に対する治療方法
CA2644297A1 (en) Prevention and treatment of cancer and other diseases
ES2644237T3 (es) Tratamiento de neurotoxicidad asociada a combinaciones de 5-FU o sus profármacos e inhibidores de DPD
ES2467968T3 (es) Regímenes de dosificación de un agente antitumoral que comprende un derivado de desoxicitidina
ES2249616T3 (es) Citidina-fosfocolina para el tratamiento de la neuropatia diabetica.
CN105263499B (zh) 用于癌症治疗的ro5503781、卡培他滨和奥沙利铂的组合
AU2013233094A1 (en) Novel antitumor agent comprising combination of three agents
ES2348996T3 (es) Potenciador de radioterapia.
JP5066737B2 (ja) シチジン誘導体を含有する持続静脈内投与用抗腫瘍剤
US20060258736A1 (en) Dosing regimen
RU2482855C2 (ru) Противоопухолевое средство, включающее производное цитидина и карбоплатин
HK1115306A (en) ANTICANCER DRUG CONTAINING α, α, α-TRIFLUOROTHYMIDINE AND THYMIDINE PHOSPHORYLASE INHIBITOR
HK1150151A (en) Anti-tumor agent comprising cytidine derivative and carboplatin
WO2006124884A2 (en) Dosing regimen